The Role of Pharmacy in Multidisciplinary Management of Oral ADT in Prostate Cancer

In this episode, “The Role of Pharmacy in Multidisciplinary Management of Oral ADT in Prostate Cancer,” expert urologists and medical oncologists explore the following question:

1. From a multidisciplinary perspective, what are the best practices for urologists, advanced practice providers, cardio-oncology clinicians, radiation oncology clinicians, and pharmacists to collaborate to support patients receiving androgen deprivation therapy (ADT)?

Led by the moderator, the faculty highlights the critical role of pharmacists within the multidisciplinary care team when managing patients receiving oral ADT and androgen receptor pathway inhibitor–based therapy. Faculty discuss how pharmacy support helps identify and manage complex drug–drug interactions, optimize dosing, and support safe initiation of therapy in patients with multiple comorbidities. The discussion also emphasizes the value of pharmacy involvement in promoting adherence and monitoring refills, particularly as more patients receive dual oral regimens. Even in settings without embedded pharmacists, the panel notes that leveraging EMR tools and specialty pharmacies can meaningfully enhance patient safety and continuity of care.

The next episode in this series, ‘Guideline-Based Management of Advanced Prostate Cancer,” features the panelists exploring how clinicians use National Comprehensive Cancer Network, American Society of Clinical Oncology, and American Urological Association guidelines to support treatment decisions and payer discussions in advanced prostate cancer. Emphasis is placed on practical access to guideline resources and consistency in their application.